SCHEMBL2368631

SCHEMBL2368631

CCOC(=O)/C(C#N)=C(/C)c1ccc(C)c(C)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.46
MAPT P10636 4/20 0.41
LMNA P02545 2/20 0.40
RAB9A P51151 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
KDM4E B2RXH2 1/20 0.39
NPC1 O15118 1/20 0.39
POLB P06746 1/20 0.39
PTP4A1 Q93096 1/20 0.39
MIF P14174 1/20 0.39
ALDH1A1 P00352 4/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
TSHR P16473 1/20 0.39
USP2 O75604 1/20 0.39
CRHBP P24387 1/20 0.39
CRHR2 Q13324 1/20 0.39
PDCD1 Q15116 1/20 0.38
CD274 Q9NZQ7 1/20 0.38
PKM P14618 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2368634 1.00 HPGD (0.46) HPGDMAPTLMNARAB9ASMN1; SMN2
SCHEMBL11138252 0.88 MAPT (0.46) HPGDMAPTLMNARAB9ASMN1; SMN2
SCHEMBL11138250 0.88 MAPT (0.46) HPGDMAPTLMNARAB9ASMN1; SMN2
SCHEMBL1554070 0.84 DHODH (0.44) HPGDMAPTLMNARAB9ASMN1; SMN2
SCHEMBL1554071 0.84 DHODH (0.44) HPGDMAPTLMNARAB9ASMN1; SMN2
SCHEMBL1554064 0.83 HPGD (0.44) HPGDMAPTLMNARAB9ASMN1; SMN2
SCHEMBL1554063 0.83 HPGD (0.44) HPGDMAPTLMNARAB9ASMN1; SMN2
SCHEMBL20358156 0.82 HPGD (0.69) HPGDMAPTKDM4EPOLBALDH1A1
SCHEMBL20358155 0.82 HPGD (0.69) HPGDMAPTKDM4EPOLBALDH1A1
SCHEMBL1553317 0.82 HPGD (0.43) HPGDMAPTLMNARAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8022076-B2 Thieno[2,3-d]pyrimidine derivatives as potassium channel modulators; antiarrhythmia agents XENTION LIMITED (GB) 2011-09-20 US disclosed
EP-1641803-B3 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2010-12-08 EP disclosed
EP-1641803-B1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2009-03-18 EP disclosed
EP-1641803-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS Xention Discovery Limited (GB) 2006-04-05 EP disclosed
US-20050026935-A1 Compounds XENTION DISCOVERY LTD. 2005-02-03 US disclosed
WO-2004111057-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION DISCOVERY LIMITED (GB) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026935-A1 Compounds KCNJ11, KCNJ1, KCNH1 HPGD 1231/4885MAPT 2978/4885LMNA 1126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.